Sarcoidosis Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Published: Dec 2023

Pages: 158

SKU: IRTNTR72397

Snapshot

Sarcoidosis Therapeutics Market 2024-2028

The global sarcoidosis therapeutics market size is estimated to grow by USD 72.82 million at a CAGR of 4.94% between 2023 and 2028.

Sarcoidosis is a rare condition that causes small granulomas in the various organs of the body. It usually affects the lungs and skin. Confirmatory diagnosis methods are required to confirm the disease after assessing the initial symptoms of the disease. Moreover, to avoid delay in diagnosis and unawareness about the treatment, various government and non-government organizations such as the Foundation for FSR and the National Heart, Lung and Blood Institute (NHLBI) of the NIH are increasing awareness about sarcoidosis and its treatment among people. Furthermore, the British Lung Foundation (BLF), a UK charity foundation, is raising awareness about the disease's cause and its symptoms and how it is diagnosed and can be treated in the UK. Consequently, the increase in the number of organizations and institutes that create awareness about sarcoidosis among people is expected to propel the growth of the market during the forecast period.

Technavio has segmented the market into Product, Distribution Channel, and Geography

The product segment includes corticosteroids, and immunosuppressants and others
The distribution channel segment includes hospital pharmacy, retail pharmacy, and online pharmacy
The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our market analysis and report examines historical data from 2018 - 2022, besides analyzing the current market scenario.

What will be the size of the Sarcoidosis Therapeutics Market During the Forecast Period?

To learn more about this report, Download Report Sample

Sarcoidosis Therapeutics Market Segmentation by Product, Distribution Channel, and Geography

Product Analysis

Corticosteroids

The market share growth by the corticosteroids segment will be significant during the forecast period. The application of corticosteroids has increased over the years, as they are the medications that perform anti-inflammatory and immune suppression activities, which are primarily required for the treatment of sarcoidosis. Due to their high therapeutic effect, corticosteroids remained the primary treatment option for sarcoidosis.

Get a glance at the market contribution of various segments Download PDF Sample

The corticosteroids segment was valued at USD 138.65 million in 2018. The growth of the corticosteroids segment is primarily driven by the increasing use of the US FDA-recommended corticosteroids for the treatment of sarcoidosis. Moreover, topical corticosteroids can be prescribed for cutaneous involvement, and eye drops may be prescribed for uveitis. Thus, such factors are expected to propel the growth of the corticosteroids segment in the global sarcoidosis therapeutics market during the forecast period.

Distribution Channel Analysis

Hospital pharmacy

Hospital pharmacies include pharmaceuticals that are purchased directly by hospitals from different pharmaceutical companies and used for the treatment of either outpatients or inpatients. Hospital pharmacies have rapidly emerged as the preferred distribution channel for sarcoidosis drugs. The reach and influence of hospitals will continue to increase as they purchase or take controlling stakes in physician practices. More hospitals are consolidating into larger healthcare systems, which can include payors, specialty services, outpatient clinics, long-term care facilities, and physician practices. Hence, such factors will drive the growth of the segment and market in focus during the forecast period.

Retail pharmacy

Retail pharmacies (usually known as community pharmacies) sell medicine and medical-related products, as well as other goods such as toiletries, cosmetics, and veterinary products, to the general public and medical practitioners. A retail pharmacy's profitability is probably going to be under pressure. Competition wages are getting tighter, and expenses are rising for everything from rent to increasingly stringent licensing and certification requirements. In addition, retail pharmacists are forced to purchase new technology and products that can help keep them up-to-date and competitive. Nevertheless, the expansion of retail pharmacies across various parts of the globe will drive the segment and will drive the growth of the market in focus during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America dominates the global sarcoidosis therapeutics market in terms of market share, which is largely due to the rising awareness about the disease in key countries such as the US and Canada. Furthermore, the increased funding for the research on sarcoidosis is expected to drive growth in the sarcoidosis therapeutics market forecast.

For example, FSR, based in the US, has worked toward the mission to stop sarcoidosis. FSR has provided annual Research Awards, Abstract Awards, and Research Support to select programs. FSR awarded and planned for USD 4 million in grants to support innovative research projects in 2021. The expected approvals of Phase II clinical-stage molecules used in the treatment of sarcoidosis, such as cibinetide and CMK389 in the US and Canada, are expected to drive market growth in this region during the forecast period.

Buy Full Report Now

Key Sarcoidosis Therapeutics Market Players

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Halozyme Therapeutics Inc.: The company offers sarcoidosis therapeutics namely OTREXUP injection.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Sarcoidosis Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.

Key Sarcoidosis Therapeutics Market Drivers

Increasing funding for research on sarcoidosis is the key factor driving market growth. Despite significant research over the past several decades, a treatment that is promising and has fewer side effects is not yet available for sarcoidosis. In addition, the etiology of the disease is not yet known, and the disease may develop in multiple organs, which is making small-scale pharmaceutical companies and universities hesitate to invest in R&D of sarcoidosis treatment. Hence, various government and private organizations are releasing funds to increase the research on sarcoidosis for the innovation of promising therapeutics that can demonstrate better safety and efficacy than the available medications.

For example, FSR has provided annual research awards, abstract awards, and research support to select programs. Collectively, FSR awarded and planned USD 4 million in grants to support innovative research projects in 2021. Thus, such funds encourage pharmaceutical companies and universities to focus on the development of promising therapeutics for the treatment of sarcoidosis, such factors will drive the market growth during the forecast period.

Significant Sarcoidosis Therapeutics Market Trends

The development of biosimilars for immunosuppressants is one of the primary market trends shaping market growth. Biosimilars are biological agents that have a resemblance to reference products that are currently licensed and authorized by the FDA in the US which is the one of the market trends and analysis. When it comes to safety, potency, purity, or effectiveness, biosimilars are identical to their corresponding reference biological therapies. Biologics such as infliximab, adalimumab, and rituximab are being used as off-label treatment options for the treatment of sarcoidosis.

Moreover, biologics are highly expensive. Consequently, several pharmaceutical companies are focusing on the development of biosimilars of biologics, as the biosimilars are of lower cost than the branded drugs. For example, eculizumab, natalizumab, and omalizumab are some of the biosimilars under clinical trials for immunosuppressants. Thus, the development of low-cost therapeutics such as biosimilars will drive market growth during the forecast period.

Major Sarcoidosis Therapeutics Market Challenges

Stringent regulations of sarcoidosis therapeutics are a challenge that affects market growth. Regulatory bodies have stringent regulations to provide marketing approval for therapeutics that are being developed for the treatment of sarcoidosis. The applicant needs to provide all the information related to the drug, which includes the results of the studies conducted in animal models, the pharmacodynamics and pharmacokinetics of the drug, and the safety profile of the drug in its clinical studies conducted in humans.

In addition, other information required includes the dosage, route of administration, dosage forms and strengths, contraindications, warnings and precautions, drug interactions, and adverse reactions. Many applications get rejected either due to inadequate drug performance or the information about the drug submitted to the US FDA is unsatisfactory. Such stringent government regulations can lead to a delay in drug approvals, which, in turn, will impede the growth of the global sarcoidosis therapeutics market during the forecast period.

Buy Now Full Report

Key Sarcoidosis Therapeutics Market Customer Landscape

The market report includes the adoption lifecycle of the market growth and forecasting, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Sarcoidosis Therapeutics Market Customer Landscape

Segment Overview

The sarcoidosis therapeutics market report forecasts market research and growth by revenue at global, regional & country levels and provides an analysis of the latest market growth and trends from 2018 to 2028.

Product Outlook
- Corticosteroids
- Immunosuppressants and others
Distribution Channel Outlook
- Hospital pharmacy
- Retail pharmacy
- Online Pharmacy
Region Outlook
- North America
  - The U.S.
  - Canada
- Europe
  - The U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- Rest of World (ROW)
  - Brazil
  - Argentina
  - Australia

Sarcoidosis Therapeutics Market Scope
Report Coverage	Details
Page number	158
Base year	2023
Historic period	2018-2022
Market forecasting period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 4.94%
Market Growth 2024-2028	USD 72.82 million
Market structure	Fragmented
YoY growth 2023-2024(%)	3.98
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 35%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Amneal Pharmaceuticals Inc., Anant Pharmaceuticals Pvt. Ltd., Atom Pharma, aTyr Pharma Inc., Fresenius SE and Co. KGaA, Halozyme Therapeutics Inc., Horizon Therapeutics Plc, Jubilant Pharmova Ltd., Kyorin Pharmaceutical Co. Ltd., Mallinckrodt Plc, Novartis AG, OrphAI Therapeutics, Pfizer Inc., Prometheus Laboratories, RELIEF THERAPEUTICS Holding SA, SarcoMedUSA Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Xentria Inc.
Market dynamics	Parent market analysis, market growth analysis, inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Sarcoidosis Therapeutics Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the sarcoidosis therapeutics market between 2024 and 2028
Precise estimation of the size of the sarcoidosis therapeutics market size and its contribution to the market in focus on the parent market
Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
Companies landscape comparing criticality of inputs and factors of differentiation
Exclusive Matrix on companies' position and classification
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
A thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of sarcoidosis therapeutics market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global sarcoidosis therapeutics market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global sarcoidosis therapeutics market 2018 - 2022 ($ million)

4.2 Product Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Product Segment 2018 - 2022 ($ million)

4.3 Distribution Channel Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Distribution Channel Segment 2018 - 2022 ($ million)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product

6.1 Market segments
- Exhibit 30: Chart on Product - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Product - Market share 2023-2028 (%)

6.2 Comparison by Product
- Exhibit 32: Chart on Comparison by Product
- Exhibit 33: Data Table on Comparison by Product

6.3 Corticosteroids - Market size and forecast 2023-2028
- Exhibit 34: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
- Exhibit 35: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
- Exhibit 36: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)

6.4 Immunosuppressants and others - Market size and forecast 2023-2028
- Exhibit 38: Chart on Immunosuppressants and others - Market size and forecast 2023-2028 ($ million)
- Exhibit 39: Data Table on Immunosuppressants and others - Market size and forecast 2023-2028 ($ million)
- Exhibit 40: Chart on Immunosuppressants and others - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Immunosuppressants and others - Year-over-year growth 2023-2028 (%)

6.5 Market opportunity by Product
- Exhibit 42: Market opportunity by Product ($ million)
- Exhibit 43: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Distribution Channel

7.1 Market segments
- Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
- Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)

7.2 Comparison by Distribution Channel
- Exhibit 46: Chart on Comparison by Distribution Channel
- Exhibit 47: Data Table on Comparison by Distribution Channel

7.3 Hospital pharmacy - Market size and forecast 2023-2028
- Exhibit 48: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
- Exhibit 49: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
- Exhibit 50: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
- Exhibit 51: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)

7.4 Retail pharmacy - Market size and forecast 2023-2028
- Exhibit 52: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
- Exhibit 53: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
- Exhibit 54: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)

7.5 Online pharmacy - Market size and forecast 2023-2028
- Exhibit 56: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million)
- Exhibit 57: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million)
- Exhibit 58: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)

7.6 Market opportunity by Distribution Channel
- Exhibit 60: Market opportunity by Distribution Channel ($ million)
- Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2023-2028 (%)
- Exhibit 64: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 China - Market size and forecast 2023-2028
- Exhibit 87: Chart on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 88: Data Table on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 89: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on China - Year-over-year growth 2023-2028 (%)

9.9 Germany - Market size and forecast 2023-2028
- Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.10 Canada - Market size and forecast 2023-2028
- Exhibit 95: Chart on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 96: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)

9.11 UK - Market size and forecast 2023-2028
- Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ million)
- Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption

11.4 Industry risks
- Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 109: Vendors covered

12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification

12.3 AbbVie Inc.
- Exhibit 111: AbbVie Inc. - Overview
- Exhibit 112: AbbVie Inc. - Product / Service
- Exhibit 113: AbbVie Inc. - Key news
- Exhibit 114: AbbVie Inc. - Key offerings

12.4 Amneal Pharmaceuticals Inc.
- Exhibit 115: Amneal Pharmaceuticals Inc. - Overview
- Exhibit 116: Amneal Pharmaceuticals Inc. - Business segments
- Exhibit 117: Amneal Pharmaceuticals Inc. - Key news
- Exhibit 118: Amneal Pharmaceuticals Inc. - Key offerings
- Exhibit 119: Amneal Pharmaceuticals Inc. - Segment focus

12.5 Anant Pharmaceuticals Pvt. Ltd.
- Exhibit 120: Anant Pharmaceuticals Pvt. Ltd. - Overview
- Exhibit 121: Anant Pharmaceuticals Pvt. Ltd. - Product / Service
- Exhibit 122: Anant Pharmaceuticals Pvt. Ltd. - Key offerings

12.6 aTyr Pharma Inc.
- Exhibit 123: aTyr Pharma Inc. - Overview
- Exhibit 124: aTyr Pharma Inc. - Product / Service
- Exhibit 125: aTyr Pharma Inc. - Key offerings

12.7 Fresenius SE and Co. KGaA
- Exhibit 126: Fresenius SE and Co. KGaA - Overview
- Exhibit 127: Fresenius SE and Co. KGaA - Business segments
- Exhibit 128: Fresenius SE and Co. KGaA - Key news
- Exhibit 129: Fresenius SE and Co. KGaA - Key offerings
- Exhibit 130: Fresenius SE and Co. KGaA - Segment focus

12.8 Halozyme Therapeutics Inc.
- Exhibit 131: Halozyme Therapeutics Inc. - Overview
- Exhibit 132: Halozyme Therapeutics Inc. - Product / Service
- Exhibit 133: Halozyme Therapeutics Inc. - Key offerings

12.9 Horizon Therapeutics Plc
- Exhibit 134: Horizon Therapeutics Plc - Overview
- Exhibit 135: Horizon Therapeutics Plc - Business segments
- Exhibit 136: Horizon Therapeutics Plc - Key news
- Exhibit 137: Horizon Therapeutics Plc - Key offerings
- Exhibit 138: Horizon Therapeutics Plc - Segment focus

12.10 Mallinckrodt Plc
- Exhibit 139: Mallinckrodt Plc - Overview
- Exhibit 140: Mallinckrodt Plc - Business segments
- Exhibit 141: Mallinckrodt Plc - Key offerings
- Exhibit 142: Mallinckrodt Plc - Segment focus

12.11 Novartis AG
- Exhibit 143: Novartis AG - Overview
- Exhibit 144: Novartis AG - Business segments
- Exhibit 145: Novartis AG - Key offerings
- Exhibit 146: Novartis AG - Segment focus

12.12 Pfizer Inc.
- Exhibit 147: Pfizer Inc. - Overview
- Exhibit 148: Pfizer Inc. - Product / Service
- Exhibit 149: Pfizer Inc. - Key news
- Exhibit 150: Pfizer Inc. - Key offerings

12.13 Prometheus Laboratories
- Exhibit 151: Prometheus Laboratories - Overview
- Exhibit 152: Prometheus Laboratories - Product / Service
- Exhibit 153: Prometheus Laboratories - Key offerings

12.14 RELIEF THERAPEUTICS Holding SA
- Exhibit 154: RELIEF THERAPEUTICS Holding SA - Overview
- Exhibit 155: RELIEF THERAPEUTICS Holding SA - Product / Service
- Exhibit 156: RELIEF THERAPEUTICS Holding SA - Key offerings

12.15 Teva Pharmaceutical Industries Ltd.
- Exhibit 157: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 158: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 159: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 160: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 161: Teva Pharmaceutical Industries Ltd. - Segment focus

12.16 Viatris Inc.
- Exhibit 162: Viatris Inc. - Overview
- Exhibit 163: Viatris Inc. - Business segments
- Exhibit 164: Viatris Inc. - Key news
- Exhibit 165: Viatris Inc. - Key offerings
- Exhibit 166: Viatris Inc. - Segment focus

12.17 Xentria Inc.
- Exhibit 167: Xentria Inc. - Overview
- Exhibit 168: Xentria Inc. - Product / Service
- Exhibit 169: Xentria Inc. - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 170: Inclusions checklist
- Exhibit 171: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 172: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 173: Research methodology
- Exhibit 174: Validation techniques employed for market sizing
- Exhibit 175: Information sources

13.5 List of abbreviations
- Exhibit 176: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

sarcoidosis therapeutics market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis